iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Get Free Report) hit a new 52-week high on Monday . The stock traded as high as $103.77 and last traded at $103.69, with a volume of 88422 shares trading hands. The stock had previously closed at $102.38.
iShares U.S. Pharmaceuticals ETF Trading Up 0.8%
The business has a fifty day moving average of $95.65 and a 200-day moving average of $90.43. The firm has a market cap of $1.48 billion, a PE ratio of 17.75 and a beta of 0.49.
Institutional Investors Weigh In On iShares U.S. Pharmaceuticals ETF
Institutional investors and hedge funds have recently modified their holdings of the company. Foundations Investment Advisors LLC bought a new position in shares of iShares U.S. Pharmaceuticals ETF in the fourth quarter worth $54,513,000. BNP Paribas Financial Markets purchased a new position in iShares U.S. Pharmaceuticals ETF during the second quarter worth about $13,108,000. Anfield Capital Management LLC purchased a new position in iShares U.S. Pharmaceuticals ETF during the fourth quarter worth about $10,007,000. JPMorgan Chase & Co. increased its stake in iShares U.S. Pharmaceuticals ETF by 89.4% in the 4th quarter. JPMorgan Chase & Co. now owns 212,805 shares of the company’s stock worth $18,052,000 after acquiring an additional 100,426 shares during the last quarter. Finally, Cetera Investment Advisers raised its holdings in shares of iShares U.S. Pharmaceuticals ETF by 675.4% in the 1st quarter. Cetera Investment Advisers now owns 109,471 shares of the company’s stock valued at $9,489,000 after acquiring an additional 95,353 shares in the last quarter.
iShares U.S. Pharmaceuticals ETF Company Profile
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
See Also
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
- A $1.5 Billion Wake-Up Call for Every AI Company on Wall Street
- AMD’s AI Bubble Could Burst Into Explosive Upside
- Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear Case
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
